CD300LF hFc Chimera, Human
| $340.00 | |
| Z04192-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $340.00 | |
| Z04192-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 42.1 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of CD300LF hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
CD300LF hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Murine norovirus (MNoV) is an important model of human norovirus (HNoV) and mucosal virus infection more broadly. CD300lf as a proteinaceous receptor for MNoV. Interestingly, its paralogue CD300ld was also sufficient for MNoV infection in vitro. CD300lf is essential for both oral and parenteral MNoV infection and to elicit anti-MNoV humoral responses in vivo. human CD300lf (huCD300lf) is not essential for HNoV infection, nor does huCD300lf inhibit binding of HNoV virus-like particles to glycans. |
| Synonyms | CLM-1; IREM-1; IgSF13; CD300F; IGSF13; NKIR; CD300f; CD300LF; CLIM1; DIgR2; LMIR3; NKIR; Pigr3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.